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DELAYED IMMUNE RECOVERY AFTER UMBILICAL CORD BLOOD
TRANSPLANTATION (UCBT) IS CHARACTERIZED BY THYMIC REGEN-
ERATION FAILURE
Krishna V. Komanduri, Lisa S. St. John, Susan Bryan, Sean Martin,
John D. McMannis, Jeffrey J. Molldrem, Richard E. Champlin, Lau-
rence J. Cooper, Laura Worth, Demetrios Petropoulos, Chitra Hosing,
Daniel M. Couriel, Marcos de Lima, Elizabeth J. Shpall Dept. of Blood
and Marrow Transplantation, Univ. of Texas M.D. Anderson Cancer
Center, Houston, TX
UCBT is a potentially curative modality for many patients with
relapsed or high-risk hematological malignancies who lack suitably
matched hematopoietic progenitor cell donors. The advent of
transplant approaches that combine multiple CB units to facilitate
transplantation into adult recipients, as well as advances in condi-
tioning regimens and supportive care, have signiﬁcantly improved
outcomes following UCBT. Despite these advances, infections
and/or relapse associated with impaired T cell reconstitution re-
mains an important source of morbidity and mortality. We pro-
spectively assessed the quantitative and functional recovery of
CD4 and CD8 T cells in 34 consecutively transplanted adult
UCBT recipients. Functional studies of CD4 and CD8 T cells
stimulated with a superantigen (staphylococcal enterotoxin B,
SEB) and cytomegalovirus (CMV) antigens revealed that SEB-
stimulated IFN responses by cytokine ﬂow cytometry (CFC) were
signiﬁcantly lower in the UCBT recipients than in control bone
marrow or peripheral blood stem cell transplant (SCT) recipients
(median values of 0.99% (n12) vs. 24.8% (n24) in the CD4
compartment and 0.62% (n14) vs. 6.37% (n9) in the CD8
compartment, respectively). Despite this, many UCBT recipients
had measurable donor-derived CMV-speciﬁc CD4 and CD8 T
cells by 3 months (4 of 11, 44% in CD4 T cells and 6 of 12, 50%
amongst CD8 T cells), indicating that primary immune responses
were derived from the naı¨ve CB graft precursors. Immunophenotypic
studies demonstrated that a higher proportion of effector and late-
effector memory cells (i.e., CCR7-CD45RA- and CCR7-CD45RA
T cells) were present in UCBT recipients than SCT recipients. The
median fraction of CCR7-negative T cells was 65% (n12, UCBT
recipients) vs. 30% (n21, other SCT recipients) in the CD4 com-
partment, and 76% vs. 31%, respectively, in the CD8 compartment.
Furthermore, the subgroup of UCBT recipients with a ratio of
CCR7 to CCR7-negative CD4T cells above themedian at day 30
after SCT survived signiﬁcantly longer (666 days vs. 224 days,
p0.03). Finally, we compared thymic regeneration (using a -chain
T cell receptor excision, TREC assay) in UCBT recipients with
three other groups of SCT recipients, including longitudinally as-
sessed autologous and allogeneic SCT recipients, as well another
group of allogeneic SCT recipients assessed cross-sectionally. Thymic
recovery was reduced at one and three months after UCBT, relative
to all other SCT recipient groups.Median TREC values (reported as
TRECs/million PBMC) at three months were 0.0 in UCBT recip-
ients (n12), 12 in autologous SCT recipients (n11), 124 in allo-
geneic SCT recipients (n27), and 2150 in a second group of allo-
geneic SCT recipients (n31) (p0.04 for all observations). These
results demonstrate that T cell immune recovery in UCBT recipients
is characterized by delayed functional rcovery and a relative predom-
inance of late memory (CCR7-) T cells, relative to other SCT recip-
ients. However, naı¨ve donor-derived CB cells are capable of primary
pathogen-speciﬁc expansion in vivo. Finally, these data suggest that
efforts to improve T cell immune reconstitution after UCBT should
be directed at improving thymic regeneration, which is likely to be
important in facilitating the recovery of naı¨ve and early memory T
cells.
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CYTOTOXIC T LYMPHOCYTE THERAPY FOR THE TREATMENT AND
PREVENTION OF ADENOVIRUS INFECTION AFTER TRANSPLANT
Catherine M. Bollard, MD Baylor College of Medicine, Houston, TX
Adenoviruses (Adv) remain a major cause of mortality and mor-
bidity in hematopoietic stem cell transplant (SCT) and cord blood
transplant (CBT) recipients. We evaluated the use of Adv-speciﬁc
cytotoxic T lymphocytes (CTL) for prophylaxis and treatment of
Adv infections post SCT. CTLs were initiated by infecting donor-
derived mononuclear cells with the either the Ad5f35pp65 or the
Ad5f35 vector. Responder cells were expanded by weekly restimu-
lation with autologous EBV-transformed B lymphoblastoid cell
lines (LCL) transduced with either Ad5f35 or Ad5f35pp65. 13 of
29 CTL lines manufactured for clinical use were predominantly
CD4 (range 12-99%), but all had a CD8 component (range
3.5-95%). 27/29 CTL lines showed speciﬁc killing of Adv beariung
targets and all lines showed killing of EBV antigen-bearing target
cells. All CTL lines generated using antigen presenting cells in-
fected with the Ad5f35pp65 vector showing killing of CMVpp65
targets which was the dominant response. Recognition of Adv and
EBV targets was not signiﬁcantly different; at 20:1 effector:target
ratio there was 16.8
13% speciﬁc lysis of Adv targets and
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17.5% lysis of EBV targets while uninfected recipient target
cells were not lysed (2
2.7%). Hexon was the immunodominant
Adv antigen in all CTL lines with Adv-speciﬁc activity. To test the
hypothesis that polyclonal hexon-speciﬁc T cells can provide pro-
tection against Adv infections in SCT recipients, we administered
donor-derived bi or tri-virus-speciﬁc CTL lines to recipients after
allogeneic SCT. We have treated 20 patients in this phase I dose
escalation study. Patients received doses ranging from 5x106/m2 to
1.35108/m2. Of 15 patients who received CTL as prophylaxis, all
remain negative for Adv, EBV and CMV. No adverse events
attributable were to CTL infusion. Increased EBV-speciﬁc T cell
frequency was detected in the peripheral blood (PB) 2wks post
infusion in all patients, likely due to the presence of this latent virus
in all. Increased CMV-speciﬁc T cell frequency was detected in the
peripheral blood (PB) 2wks post infusion in all patients who re-
ceived tri-virus speciﬁc CTL. However, there was no signiﬁcant
rise in Adv-speciﬁc T cell frequency post-infusion except in the 5
patients who had recent or active infection. All patients cleared
their Adv infection. This included one patient who received CTL
(5x106/m2) as treatment for Adv disease. This patient had Adv
pneumonia requiring ventilatory support. Post-CTL the patient
made a dramatic clinical recovery, was weaned off mechanical
ventilation, and discharged a month after infusion. In contrast to
the prophylaxis group, this patient had a substantial rise in Adv-
speciﬁc T cells in PB by 4wks post CTL, which coincided with
clinical recovery and clearance of Adv from the tracheal aspirate,
suggesting that the infused cells were effective in vivo. Adoptive
immunotherapy for Adv appears safe but expansion of Adv-speciﬁc
CTL in vivo may require the presence of antigen to stimulate the
infused cells. Strategies to translate this approach to the cord blood
setting will be discussed.
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STRATEGY TO COMBAT OPPORTUNISTIC INFECTIONS AFTER UMBILI-
CAL CORD BLOOD TRANSPLANTATION (UCBT) - MONITORING OF
MULTIPLE PATHOGENS WITH A NOVEL MULTIPLEX PCR SYSTEM AND
INFUSION OF EX-VIVO EXPANDED CD4 T-CELLS (CD4-DLI)
Tomohiro Morio, MD, PhD Department of Pediatrics and Developmen-
tal Biology Tokyo Medical and Dental University Graduate School of
Medicine Centre for Cell Therapy, Tokyo Medical and Dental University
Medical Hospital
Infectious complications are a major cause of morbidity and
mortality in patients undergoing hematopoietic stem cell trans-
plantation. Although the risk of serious infection after pediatric
umbilical cord blood transplantation (UCBT) is reported to be
comparable to that with unmanipulated BM, several line of evi-
dence now shows high incidence of EBV-related complications,
VZV reactivation, HHV6 infection, and CMV infection in CBT-
recipients. A system for sensitive and rapid monitoring of multiple
viruses is fundamental to pinpoint target pathogen(s) and to start
anti-microbial therapy in a timely manner. We have developed a
novel system that employs a melting curve analysis on multiplex
PCR products, a system that is designed to detect 17 viruses:
HSV1, HSV2, VZV, EBV, CMV, HHV6, HHV7, HHV8, BK
virus, JC virus, Parvovirus B19, HBV, HIV1, HIV2, HTLV1,
HTLV2, and HCV. The lowest detectable level is less than 20
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